| Literature DB >> 32695828 |
Dorin Dragoș1,2, Maria Mirabela Manea1,3, Delia Timofte4, Dorin Ionescu1,2.
Abstract
Diabetic nephropathy (DN) is a leading cause of kidney morbidity. Despite the multilayered complexity of the mechanisms involved in the pathogenesis of DN, the conventional treatment is limited to just a few drug classes fraught with the risk of adverse events, including the progression of renal dysfunction. Phytoceuticals offer a promising alternative as they act on the many-sidedness of DN pathophysiology, multitargeting its intricacies. This paper offers a review of the mechanisms underlying the protective action of these phytoagents, including boosting the antioxidant capabilities, suppression of inflammation, averting the proliferative and sclerosing/fibrosing events. The pathogenesis of DN is viewed as a continuum going from the original offense, high glucose, through the noxious products it generates (advanced glycation end-products, products of oxidative and nitrosative stress) and the signaling chains consequently brought into action, to the harmful mediators of inflammation, sclerosis, and proliferation that eventually lead to DN, despite the countervailing attempts of the protective mechanisms. Special attention was given to the various pathways involved, pointing out the ability of the phytoagents to hinder the deleterious ones (especially those leading to, driven by, or associated with TGF-β activation, SREBP, Smad, MAPK, PKC, NF-κB, NLRP3 inflammasome, and caspase), to promote the protective ones (PPAR-α, PPAR-γ, EP4/Gs/AC/cAMP, Nrf2, AMPK, and SIRT1), and to favorably modulate those with potentially dual effect (PI3K/Akt). Many phytomedicines have emerged as potentially useful out of in vitro and in vivo studies, but the scarcity of human trials seriously undermines their usage in the current clinical practice-an issue that stringently needs to be addressed.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32695828 PMCID: PMC7362309 DOI: 10.1155/2020/5710513
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Pathways and mediators of DN relevant for the action mechanisms of the phytoagents active in DN. The schematic is meant to highlight the complexity of the factors and interconnections involved in DN pathogenesis, although it leaves out many of them lest it might become unintelligible. HG↑: activated/increased/induced by high glucose (HG); HG↓: inactivated/decreased by HG, mes.: mesangial; exp.: expansion; hypercell.: hypercellularity; continuous arrowhead-ended lines indicate a stimulating effect; dotted diamond-ended lines indicate an inhibitory effect.
Phytoceuticals effective in preventing diabetic nephropathy in animal models of DN. If not otherwise specified, the indicated dose was the daily dose and the route of administration was oral (generally by gastric gavage). If the strain of animals is not specified, that means that it was not specified in the cited article. The phytoceuticals are divided in plant materials, plant combinations, and plants. The plant materials (i.e., phytocompounds) are presented alphabetically according to the name of the medicinal plants of origin (which is put in parentheses, preceding the name of the plant material). For several phytocompounds there is no predominant plant source—those phytocompounds have, each, many sources. The studies that demonstrated actual nephroprotection are marked by “(NP)” in the “Type of study, model” column. The type of the study is also marked by the letters H=human study, T=in vitro study, V=in vivo study, T, V=in vivo and in vitro study also placed in parentheses in the “Type of study, model” column.
| Herb/phytochemical, dose, and route of administration | Type of study, model | Findings | Ref. |
|---|---|---|---|
| Plant materials | |||
| ( | (NP) (V) eNOS−/− mice, STZ; | ↓ albuminuria, KiHPCh; on podocytes: ↑ adhesion, ↓ motility, ↑ stability of actin cytoskeleton through Drebrin-1 (DBN1) dephosphorylation; ↑ protein phosphatase 2 A → ↓ p65 NF- | [ |
| ( | (NP) (T, V) HG-cultured immortalized mouse mesangial cells SV40 MES 13; male KK-Ay mice with HFD-induced DM and male C57BL/6J mice | ↑SIRT1 → ↓ p65 acetylation → ↓ NF- | [ |
| ( | (NP) (T, V) male SD rats, STZ; ER stress was induced in cultured human podocytes with tunicamycin | ↓ albuminuria, s-creat, BUN, ECM expansion, phosphorylation of eukaryotic initiation factor 2 | [ |
| ( | (NP) (T, V) C57BL/6J mice, STZ; HG-cultured immortalized mouse podocytes. | ↓ albuminuria, BUN, s-creat; ↓ KiHPCh; ↓ RAS (↓ renin); ↓ MCP-1, TNF- | [ |
| ( | (NP) (H) hypertensive T2DM patients with blood pressure and fasting plasma glucose adequately controlled by treatment. Low-quality (J1, i.e., the randomization method not described, the trial was not double-blinded, nor placebo-controlled, no description of withdrawals and dropouts) trial | ↓ albuminuria, u-osteopontin, u-KIM-1, vascular cell adhesion molecule-1, C-reactive protein, MDA, u-8-hydroxy-2′-deoxyguanosine; ↑ SOD, total-antioxidant capacity, s-high molecular weight-adiponectin; improved renal hemodynamics | [ |
| ( | (NP) (V) male Wistar rats, high-fat diet + STZ | ↓ s-glu, lipids, albuminuria, NF- | [ |
| ( | (NP) (V) male SD rats, STZ | ↓ s-glu, KW/BW, proteinuria, BUN, s-creat, KiHPCh, AGEs, RAGE, p-PKC- | [ |
| ( | (NP) (V) male SD rats, STZ | ↓ s-glu, proteinuria, BUN, s-creat, KW, TGF- | [ |
| ( | (NP) (V) male SD rats, high-sugar, and high-fat diet + STZ | ↓ proteinuria, BUN, s-creat, KiHPCh; ↑ EP4 and G | [ |
| ( | (NP) (V) male SD rats, STZ + high-fat diet | ↓s-glu, proteinuria, albuminuria, BUN, s-creat, TG, TC, LDL-C, collagen 4, TGF- | [ |
| ( | (NP) (T, V) male SD rats, high-glucose, and high-fat diet + STZ; HG-incubated renal cortical cells | ↓ KW/BW, proteinuria, BUN, s-creat, PGE2, renal prostaglandin E2 receptor 1, KiHPCh, G | [ |
| ( | (T) normal rat renal tubular epithelial (NRK-52E) and human kidney proximal tubular (HK-2) cells | ↓ apoptosis (↓ cytochrome c, Bax, caspase-3 and caspase-9); ↑ PI3K/Akt; ↑ Nrf2, HO-1; ↓ mitochondrial function (↓ mitochondrial membrane potential); ↓ ROS production; ↑ GSH, SOD | [ |
| ( | (T) HG-cultured immortalized mouse (MPC5) podocytes | ↓ apoptosis; ↑ nephrin and podocin; ↑ AMPK activation; ↓ mTOR →↑ autophagy | [ |
| ( | (T) HG-cultured NRK-52E and HK-2 cells exposed to hypoxia | ↑ hypoxia/HG-induced HIF-1 | [ |
| ( | (NP) (V) | ↓ s-glu, area under the curve at OGTT, proteinuria, u-8-hydroxy-2′-deoxyguanosine, angiotensin II, angiotensin II type 1 receptor, p22-phox, p47-phox, p-extracellular regulated protein kinases (p-ERK1/2), p-p38MAPK, KiHPCh; ↑ insulin, p-PI3K, p-Akt | [ |
| ( | (NP) (V) male SD rats, STZ | ↓ albuminuria and s-creat; ↑ u-creat and CrCl; ↓ endothelin-1, LPO, ALT, and expression of fibronectin; ↑ free thiols | [ |
| ( | (NP) (V) male SD rats, STZ | ↓ albuminuria, interstitial fibrosis | [ |
| ( | (NP) (V) male Wistar rats, ischemia-reperfusion + lipopolysaccharide | ECG: ↓ 3-NT, ONOO−, ∙OH, MPO, protein nitration, LPO, s-uric, BUN, s-creat, proteinuria; ↑ SOD, CAT, GPx, GSH; EGCG: ↓ s-glu, proteinuria, albuminuria, TC, TG, BUN, s-creat, glomerular and tubulointerstitial injury, AGEs, LPO, iNOS, COX-2, NF- | [ |
| ( | (NP) (V) male Wistar rats, alloxan | ↓ s-glu, HbA1c, s-urea, peroxidase activity, Amadori product, nonprotein thiols | [ |
| ( | (T) HG- (15 or 25 mM-) cultured immortalized mouse podocytes | ↓ROS production, IL-1 | [ |
| ( | (T) AGE-treated rat kidney tubular epithelial cell line NRK-52E | ↑ PI3k/AKT → ↑ autophagy (↑ autophagic vacuolization (LC3, ratio LC3II/LC3I and Beclin)) → ↓ AGEs-induced apoptosis (↓ Bax and apoptosis-inducing factor, cleaved caspase-3 and caspase cascade activation) | [ |
| ( | (NP) (T, V) male Wistar rats, STZ; HG-cultured podocytes | ↓ KW/BW, proteinuria, EMT of podocytes, ECM expansion, GS, GBM thickening, podocyte foot processes effacement, renal fibrosis, caveolin-1 Tyr(14) phosphorylation; ↑ CrCl, stabilization of caveolin-1 and | [ |
| ( | (NP) (V) male Wistar rats, STZ + nicotine | ↓ TC, TG, PL, MDA, | [ |
| ( | (NP) (V) male SD rats, STZ | ↓ s-glu, BUN, proteinuria, macrophage infiltration, TNF- | [ |
| ( | (T) rat mesangial cell line HBZY-1 | ↓ ROS generation, MDA, apoptosis (increased by AGEs); ↑ SOD (decreased by AGEs) | [ |
| ( | (NP) (T, V) male SD rats, STZ; HG-induced HK-2 cells | ↓ albuminuria, s-creat, BUN, KiHPCh; ↑ p-AMPK → ↓ p-mTOR; AMPK activation → ↑ autophagy → ↓ apoptosis (↓ caspase-3) | [ |
| ( | (NP) (V) male Wistar rats, STZ | ↓ s-glu, polyphagia, polydipsia, TC, TG, s-creat, proteinuria, KW/BW, MDA, MPO, AGEs, KiHPCh including GBM thickening; ↑ BW, CrCl, HDL-C, SOD, CAT, GSH | [ |
| ( | (NP) (V) male Wistar rats, STZ | ↓ s-glu, HbA1c, s-creat, BUN, proteinuria, NO, TBARS, MDA; ↑ CrCl, SOD, CAT | [ |
| ( | (NP) (V) male Munich-Wistar rats, STZ | ↓ albuminuria, MDA, PKC, TGF- | [ |
| ( | (NP) (V) male Munich-Wistar rats; STZ | ↓ albuminuria, KiHPCh, 3-NT, MDA, PKC, TGF- | [ |
| ( | (NP) (V) male Wistar rats, STZ | ↓ s-urea, s-uric, s-creat, AGEs, TNF- | [ |
| ( | (T) HK-2 cells | ↓ autophagy, apoptosis, caspase-3, Bax; ↑ Bcl-2, p-Akt | [ |
| ( | (NP) (V) male SD rats, STZ + high-fat diet | ↓ s-glu, fructosamine, s-creat, BUN, MDA, NO, NF- | [ |
| Curcumin analogue (B06), 0.2 mg/kg for 6 weeks | (V) male SD rats and Institute of Cancer Research (ICR) mice, STZ | ↓ TNF- | [ |
| (many sources) dihydroquercetin (a flavanonol a.k.a taxifolin), | (NP) (T, V) SD rats, high-fat diet + STZ; HG-cultured rat kidney mesangial cells (HBZY-1) and human proximal renal tubular epithelial cells (HK-2 = human kidney 2) |
| [ |
| (Many sources) ellagic acid (a phenolic acid), | (NP) (T, V) male Wistar albino rats, high-fat diet + STZ; HG-cultured rat NRK 52E proximal tubular epithelial cells | ↓ s-glu, polyphagia, BW, HbA1c, insulin resistance, TC, LDL-C, VLDL-C, FFA, TG, GOT, GPT, ALP, MDA, s-creat, BUN, proteinuria, KiHPCh, NF- | [ |
| (Many sources) ferulic acid (a hydroxycinnamic acid), ( | (NP) (T, V) male Wistar rats, STZ; HG-induced normal rat kidney epithelial-like (NRK-52E) cells | ↓ gluc, BUN, s-creat, s-uric, albuminuria; ↓ KiHPCh; ↓ ROS, NO, protein carbonyl, MDA, ↑ SOD2, catalase, ↑ GSH/GSSG ratio; ↓ AGEs, ↓ xanthine oxidase, ↓ hydroxyproline (fibrosis); ↓ MAPK (↓ phosphorylation of p38, JNK, and ERK1/2 MAPKs); ↓ neutrophil infiltration (↓ MPO); ↓ TNF- | [ |
| (Many sources) isorhamnetin (a methoxylated flavonol), | (NP) (T, V) male SD rats, high-fat diet + STZ; glomerular mesangial cells, lipopolysaccharide | ↓ u-osteopontin, u-KIM-1, albuminuria, NF- | [ |
| (Many sources) mangiferin (a xanthone), ( | (NP) (T, V) male SD rats, STZ; HG-cultured immortalized mouse podocytes (MPC5) | ↓ albuminuria, ↓ glomerular ECM expansion, ↑ nephrin; ↑ autophagy; ↑ p-AMPK; ↓ p-mTOR; ↑ p-ULK1 | [ |
| (Many sources) myricetin (a flavonol), 1.0 mg/kg for 12 weeks | (NP) (V) male albino Wistar rats, STZ + Cd | ↓ albuminuria, TC, TG, FFA, PL, LDL, VLDL, 3-HO 3-methylglutaryl coenzyme A reductase, SREBP-1a, SREBP-1c, and SREBP-2, TGF- | [ |
| (Many sources) quercetin (a flavonol), 10 mg/kg for 4 weeks | (NP) (V) adult C57BL/6J mice, STZ | ↓ polyuria, s-glu, TG, proteinuria, s-uric, s-urea, s-creat, superoxide anions, KiHPCh, apoptosis | [ |
| (many sources) resveratrol (a polyphenolic phytoalexin and a stilbenoid) ( | (NP) (T, V) male | ↓ albuminuria, s-creat, KiHPCh; ↑ LC3-II/LC3-I and synaptopodin, ↓ cleaved caspase-3; ↑ miR-18a-5p (via targeting atactic telangiectasis mutation) → ↓ apoptosis (↓ cleaved caspase-3) and ↑ autophagy (↑ LC3-II/LC3-I) | [ |
| (Many sources) resveratrol ( | (NP) (T, V) | ↓ microalbuminuria, s-creat, BUN; ↓ KiHPCh, ↑ nephrin, ↓ apoptosis (↓ cleaved caspase-3 and Bax); ↑ autophagy (↑ LC3-II and synaptopodin, ↑ Atg5, ↓ p62, ↑ number of autophagosomes); ↓ miR-383-5p → ↑ autophagy → ↓ apoptosis of podocytes | [ |
| (Many sources) resveratrol ( | (NP) (T, V) male SD rats, HG-cultured NRK-52E (rat renal proximal tubular cells) | ↓ TNF- | [ |
| ( | (T) HG-cultured human renal proximal tubule HK-2 cells | ↑ Nrf2-antioxidant responsive elements and the downstream genes NAD(P)H:quinone oxidoreductase 1, HO-1, and glutamate cysteine ligase catalytic subunit; ↓ iNOS, IL-6, IL-1 | [ |
| ( | (T) coculture system of mesangial cells HBZY-1 and macrophages | ↓ macrophage migration, IL-6, MCP-1 (increased by AGEs); ↑ GPx and CAT (decreased by AGEs) | [ |
| ( | (V) rats, STZ | ↓ polydipsia, polyuria, s-glu, glycosylated protein, TBARS, ameliorates renal dysfunction | [ |
| ( | (T) HG-cultured immortalized mouse podocytes (MPC5) | ↓ EMT (↑ nephrin and podocin), ↓ apoptosis (↓ caspase-3), ↑ autophagy by regulating Pim1/p21/mTOR (↓ p-mTOR mainly dependent on Pim1) | [ |
| ( | (NP) (V) male Wistar rats, STZ | ↓ KiHPCh including podocyte foot processes effacement, proteinuria, ROS production, S-nitrosylation of proteins, MMP-9; ↑ podocyte slit diaphragm proteins (nephrin, podocin) | [ |
| ( | (NP) (T, V) eNOS−/−) mice + STZ (an accelerated DN model); HG-cultured murine podocytes | ↓ albuminuria, KiHPCh, oxidative stress, superoxide, NOX4; ↑ SIRT1, SIRT1-mediated deacetylation of NF- | [ |
| ( | (T) HG-cultured immortalized proximal tubular cells HK-2 | ↓ integrin-linked kinase, EMT, MMP-9/TIMP-1 ratio | [ |
| ( | (NP) (V) | ↓ albuminuria, ECM, TGF- | [ |
| ( | (NP) (V) female adult Wistar rats, STZ | ↓ s-glu, KW, albuminuria, s-creat, tubulointerstitial injury, IL-6, TNF- | [ |
| ( | (T) HG-cultured rat mesangial cell line (HBZY-1) | ↓ cell proliferation and stops cell cycle progression; ↓ fibronectin, p-p38MAPK, p-cAMP response element-binding protein, CTGF; ↑ PPAR- | [ |
| ( | (NP) (T, V) OVE26 mice (a model of T1DM and DN); HG- (25 mM) cultured mouse podocytes | ↓ NOX4, superoxide production, podocyte apoptosis, albuminuria | [ |
| ( | (NP) (H) randomized, double-blind, placebo-controlled trial on patients with T2DM, eGFR >30 mL/min/1.73 m2 and albuminuria >300 mg/24 h (despite maximal renin-angiotensin system inhibitor therapy for ≥6 months). High-quality (J5) trial | ↓ albuminuria, TNF- | [ |
| ( | (V) spontaneously hypertensive rats, STZ | ↓ TGF- | [ |
| ( | (T) HG-induced | ↓ apoptosis, ↑ nephrin and podocin, ↓ | [ |
| ( | (T) HG-cultured mouse podocytes | ↓ apoptosis, LDH, ROS; ↓ IL-1 | [ |
| ( | (NP) (T, V) male SD rats, high-fat diet + STZ; HG-cultured human mesangial cells | ↑ autophagy, ↓ fibrosis (fibronectin, collagen 4) by means of miR-141-3p/PTEN/Akt/mTOR (↑ PTEN, ↓ p-Akt, ↓ p-mTOR) | [ |
| ( | (T) HG-cultured human renal mesangial cell | ↓ CTGF, ICAM-1, MCP-1, TGF- | [ |
|
| |||
| Plant combinations | |||
| Huangqi decoction (an extract from 7 herbs: astragalus, poria, trichosanthes roots, ophiopogon, schisandra, licorice and rehmannia), 1.08, 0.36, and 0.12 g/kg for 14 weeks | (NP) (V) male | ↓ s-glu, s-glu increase at OGTT, polyphagia, polydipsia, polyuria, BW, insulin resistance, HbA1c, albuminuria, s-creat, BUN, KiHPCh, p-Akt, GLUT (glucose transporter)1; ↑ GFR, p-insulin receptor (IR), p-IR substrate, p-PI3K, GLUT4 | [ |
| Shen-Yan-Fang-Shuai Formula (SYFSF)—a traditional Chinese formula composed of | (NP) (T, V) Wistar rats uninephrectomy + high-fat diet + STZ; high-glucose cultured rat renal mesangial cell line (HBZY-1) | ↓ albuminuria, TC, TG, s-creat, interstitial expansion, GS, MCP-1, TGF- | [ |
| Tangke decoction, 18 mg/kg for 12 weeks (prevention) or for 8 weeks (treatment) | (NP) (V) male SD rats, STZ | ↓ KW, KW/BW, s-glu, proteinuria, albuminuria, TGF- | [ |
| Tangshen Formula ( | (NP) (T, V) C57BLKS/J | ↓ proteinuria, KiHPCh; ↓ promyelocytic leukemia zinc finger protein, ↓ collagen 3 accumulation; ↑ autophagy; ↓ cell proliferation | [ |
| Tangshen Formula 8 g × 2/d for 24 weeks | (NP) (H) six-center randomized, double-blind, placebo-controlled trial on 180 patients with DKD. High-quality (J5) trial | ↓ proteinuria, ↑ eGFR, ↓ liver-type fatty acid binding protein | [ |
| Qidan Dihuang decoction, | (NP) (V) male SD rats, STZ | ↓ s-creat, proteinuria, KiHPCh, | [ |
|
| |||
| Plants | |||
|
| (NP) (V) male SD rats; unilateral nephrectomy + STZ | ↓ KW, albuminuria, BUN, s-uric, renal fibrosis/GS, MDA, 8-hydroxy-2′-deoxyguanosine, NOX4, p-p38MAPK, p-Akt, TGF- | [ |
|
| (NP) (V) male SD rats; unilateral nephrectomy + STZ | ↓ TG, TC, TNF- | [ |
|
| (NP) (V) mice after unilateral nephrectomy + high-fat diet + STZ | ↓ gluc, s- creat, BUN, albuminuria; ↓ KiHPCh; ↑ autophagy- (SIRT-1, ATG5, ATG12), ↑ autophagy dynamics (↑ LC3B-II, ↓ p62); ↓ mitochondrial fragmentation; ↓ hepatic injury (ALT, AST, hepatic necrosis, liver lipid accumulation); ↓ TNF- | [ |
|
| (NP) (V) male albino Wistar rats, STZ | ↓ BW, polyuria, HbA1c, albuminuria, s-creat, BUN, TG, TC, LDL-C, KiHPCh; ↑ HDL-C, u-creat, u-urea | [ |
|
| (NP) (V) Wistar rats, STZ + nicotinamide | ↓ TNF- | [ |
|
| (NP) (V) male Wistar rats, STZ | ↓ s-glu, s-creat, BUN, MDA, proteinuria, KW/BW; ↑ urinary volume (reduced by diabetes) ( | [ |
|
| (NP) (V) male Wistar rats, alloxan | ↓ s-glu, s-urea, s-creat, s-uric, MDA, NO, advanced oxidation protein products, KiHPCh ↓SOD, CAT, GPx ( | [ |
|
| (NP) (V) male albino Wistar rats, STZ + Cd | ↓ s-glu, glucagon, TC, TG, LDL-C, ESR, s-urea, s-uric, s-creat; ↑ total protein, albumin, insulin, HDL-C, neutrophil count, and hematocrit | [ |
|
| (NP) (V) male Wistar rats, nicotinamide + STZ | ↓ s-glu, s-uric, s-creat, lipid, AGEs, TBARS. ↑ SOD, GSH | [ |
|
| (V) female albino Wistar rats, alloxan | Maintained the ionic balance and renal Na+-K+ ATPase activity, ↓ s-glu, LPO; ↑ GPx, CAT, SOD, GSH | [ |
|
| (NP) (V) male albino Wistar rats, STZ + Cd | ↓ s-glu, s-creat, BUN, TC, VLDL-C, LDL-C, TG, FFA, PL, KiHPCh; ↑ insulin, HDL-C | [ |
|
| (NP) (V) male Wistar rats, high-fat diet + STZ | ↓ s-glu, TG, insulin resistance, PKC- | [ |
|
| (NP) (V) male Wistar rats, STZ | ↑ BW; ↓ s-glu, glucosuria, albuminuria; ↓ glomerular filtration rate; ↓ KW/BW; ↓ laminin, fibronectin; ↑ CAT, GPx, GRed, GST | [ |
|
| (NP) (V) C57BL/6J mice, high-fat diet + nicotinamide + STZ | ↓ s-glu, s-creat, TG, TC carboxymethyl lysine (an AGE), TGF- | [ |
|
| (T) rat mesangial cells (HBZY-1) | ↓ mesangial cell proliferation and fibrogenesis, collagen 4, fibronectin, and TGF- | [ |
|
| (NP) (V) | Morroniside: ↓ TG, ROS, TBARS, AGEs, SREBP-1 and SREBP-2, NF- | [ |
|
| (NP) (V) male SD rats, STZ | ↓ TG, TC, LDL-C, ALT, AST, ALP, s-urea, s-creat; ↑ HDL-C | [ |
| Danhong (extracted from | (NP) (V) male SD rats; unilateral nephrectomy + high-fat diet + STZ | ↓ BUN, s-creat, cystatin C, proteinuria, TC, LDL-C, p38MAPK, KiHPCh; ↑ HDL-C, PPAR | [ |
|
| (NP) (H) hospital-based single-center prospective open-label randomized case-control interventional study on patients with DN with proteinuria >500 mg or albuminuria >300 mg/d, s-creat ≤2.5 mg/dL and hypertension controlled with a single drug. Low-quality (J1, i.e., the randomization method not described, the trial was not double-blinded, nor placebo-controlled, no description of withdrawals and dropouts) trial | ↓ systolic and diastolic blood pressure, s-glu, LDL, proteinuria, TGF- | [ |
|
| (NP) (V) male Kunming mice, STZ | ↓ s-glu, s-creat, BUN, s-albumin ( | [ |
|
| (NP) (V) albino Wistar rats, nicotinamide + STZ | ↓ s-glu, AST, ALT, ALP, TC, LDL, VLDL, TG, s-creat, MDA, several fatty acid synthesis genes, SREBP, NF- | [ |
|
| (NP) (V) SD rats 5/6 nephrectomy | ↓ BUN, s-creat, KiHPCh, systolic blood pressure, MDA; ↑ CrCl | [ |
|
| (NP) (V) male Wistar rats, STZ | ↓ BUN, s-creat, albuminuria, fibronectin, collagen 4, KiHPCh, ROS production, p-Smad2/3; ↑ CrCl, Nrf2 | [ |
|
| (NP) (V) rats, nicotinamide + STZ | ↓ s-glu, s-urea, s-creat, albuminuria, NF- | [ |
|
| (NP) (V) Wistar rats, alloxan | ↓ s-glu, s-creat, BUN, bilirubin, AST, ALT, TG, TC, TBARS/MDA, IL-6, IL-1 | [ |
|
| (NP) (V) male Wistar rats, nicotinamide + STZ | ↓ s-glu, HbA1c, s-uric, s-creat, BUN, TC, TG, LDL, VLDL, KW/BW, polyuria, albuminuria, u-creat, KiHPCh, TBARS, AGEs; ↑ BW, s-insulin, HDL-C, CrCl, GSH, SOD | [ |
|
| (NP) (V) male Munich-Wistar rats, STZ | ↓ albuminuria, glomerular volume, tubulointerstitial injury (ALT), collagen 4, ICAM-1, IL-1, TNF- | [ |
|
| (T) HG-cultured mesangial cells |
| [ |
|
| (NP) (V) male KK-Ay (KK/UPJ-Ay/J) mice (animal model for human type 2 DN) | ↓ s-glu, BW, insulin resistance, TG, glomerular lesions; ↑ glucose tolerance | [ |
|
| (NP) (V) male Wistar rats, STZ | ↓ KW, polyphagia, polydipsia, polyuria, proteinuria, s-glu, glycosylated protein, N | [ |
|
| (NP) (V) C57BL/6 mice, STZ (T1DM model); | ↑ BW (decreased in T1DM model); ↓ BW, plasma insulin levels, insulin resistance (increased in T2DM model); ↓ s-glu, HbA1c, albuminuria, s-creat, oxidative stress, HO-1, NF- | [ |
|
| (NP) (V) male Wistar rats, alloxan | ↓ s-glu, KW, fructosamine, HbA1c, MDA, s-creat, BUN; ↑ BW, SOD | [ |
|
| (NP) (V) male Kunming mice, STZ | ↓ s-glu, BUN, s-creat, s-uric, TC, TG, VLDL-C, LDL-C, MDA, KiHPCh, KW/BW, s-albumin ( | [ |
|
| (NP) (T, V) male SD rats, STZ; HG-cultured (25 mM) human mesangial cell | ↓ TGF- | [ |
|
| (NP) (T, V) male C57BL/6 mice; HG-cultured mesangial MES-13 cells | ↓ CrCl, polyuria, microalbuminuria, mesangial expansion, collagen 4- | [ |
|
| (NP) (V) Wistar rats, STZ | ↓ s-glu, s-glu increase at OGTT, TC, TG, LDL-C, VLDL-C, HbA1c, proteinuria, albuminuria, s-creat, BUN, KW/BW, polyphagia, polydipsia, polyuria, MDA, KiHPCh including GS; ↑ BW, HDL-C, s-protein, s-albumin, CrCl, GSH, SOD, CAT | [ |
|
| (NP) (V) male BALB/c mice, STZ | ↓s-glu, s-glycosylated protein, TC, BUN, s-creat, proteinuria, IL-6, interferon- | [ |
|
| (NP) (V) female Wistar rats, alloxan | ↓ s-glu, TC, TG, LDL-C, s-uric, s-urea, s-creat, KiHPCh; ↑ HDL-C, BW | [ |
|
| (NP) (H) stable diabetic CKD patients. Low-quality (J1, i.e., the randomization method not described, the trial was not double-blinded, no description of withdrawals and dropouts), low-powered trial | ↓ s-creat, progression of CKD, endothelial dysfunction markers (homocysteine, IL-6); ↑ CrCl | [ |
|
| (V) male Wistar rats, high-fat diet + STZ | ↓ s-glu, TG, insulin resistance, KiHPCh, MDA, GPx, NF- | [ |
|
| (NP) (V) SD rats, STZ | ↓ s-glu; renoprotective | [ |
|
| (V) male Wistar rats, STZ | ↑ glutathione; ↓ HO-1, p47phox; ↑ autophagy (↑ LC3B-II, ↓ p62/sequestosome 1) | [ |
↓: decreased/prevented the increase (of activity (for enzymes)/level (for biochemical parameters))/inhibited/inactivated/blocked/suppressed/downregulated (about pathways, enzymes, receptors, cytokines, etc.); ↑: increased/prevented the decrease (of activity (for enzymes)/level (for biochemical parameters))/stimulated/activated/upregulated; →: leading to/inducing; 3-NT: 3-nitrotyrosine; AGEs: advanced glycation end-products; ALP: alkaline phosphatase; ALT: alanine aminotransferase/transaminase; AMPK: 5′ adenosine monophosphate-activated protein kinase; AST: aspartate aminotransferase/transaminase; Bax: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma 2 protein; BUN: blood urea nitrogen; BW: body weight; CAT: catalase; Cd: cadmium (generally given as cadmium chloride CdCl2); COX-2: cyclooxygenase 2; CrCl: creatinine clearance; CTGF: connective tissue growth factor; DN: diabetic nephropathy; ECM: extracellular matrix; EMT: epithelial-mesenchymal transdifferentiation; eGFR: estimated glomerular filtration rate; eNOS: endothelial NO synthase; eNOS−/−: endothelial nitric oxide synthase-null; EP4: E prostanoid receptor 4; ER: endoplasmic reticulum; FFA: free fatty acids; GBM: glomerular basement membrane; GFR: glomerular filtration rate; GPx: glutathione peroxidase; GRed: glutathione reductase; GS: glomerulosclerosis; GSH: reduced glutathione; GST: glutathione S-transferase; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; HDL-C: HDL-cholesterol; HG: high glucose, i.e., glucose 30 mM if not otherwise specified (the physiological concentration being 5 mM); HIF-1α: hypoxia-inducible factor 1α; HO-1: heme oxygenase-1; ICAM: intercellular adhesion molecule; IL: interleukin; iNOS: inducible NO synthase; IκBα: inhibitor of NF-κB; JNK: c-Jun N-terminal kinase; KiHPCh: kidney histopathological changes; KIM-1: kidney injury molecule-1; KW: kidney weight; KW/BW: (kidney weight)/(body weight) = kidney index; LC3B-II: light chain 3B II; LDL: low-density lipoprotein; LDL-C: LDL-cholesterol; LPO: lipid peroxidation; MAPK: mitogen-activated protein kinase; MC: mesangial cells; MCP: monocyte chemoattractant/chemotactic protein; MDA: malondialdehyde; miR: microRNA; miR-141-3p: a member of the microRNA- (miR-) 200 family; MMP: matrix metalloproteinase; MPO: myeloperoxidase; NADPH: reduced nicotinamide-adenine dinucleotide phosphate; NF-κB: nuclear factor kappa-B (nuclear factor kappa-light-chain-enhancer of activated B cells); NLRP3: nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3; NO: nitric oxide; NOX: NADPH oxidase; Nrf2: nuclear factor erythroid-derived 2; OGTT: oral glucose tolerance test; p-: phospho-/phosphorylated; PARP: poly (ADP-ribose) polymerase; PI3K: phosphatidylinositol 3-kinase; PKC: proteinkinase C; PL: phospholipids; PPAR: peroxisome proliferator-activated receptor; PTEN: phosphatase and tensin homolog; RAGE: receptor for advanced glycation end-products; RAS: renin-angiotensin system; ROS: reactive oxygen species; s-: serum level of; s-creat: serum level of creatinine; SD: Sprague Dawley, a strain of rats; SERCA2b: sarcoendoplasmic reticulum Ca2+ ATPase 2b; s-glu: serum/plasma/blood level of glucose; SIRT1: sirtuin1; Smad proteins: signal transducers for receptors of TGF-β superfamily; SOD: superoxide dismutase; SREBP: sterol regulatory element-binding protein; STZ: streptozotocin; s-urea: serum level of urea; s-uric: serum level of uric acid; T1DM/T2DM: type 1/2 diabetes mellitus; TBARS: thiobarbituric acid reactive substances; TC: total cholesterol; TG: triglyceride/triacylglycerol; TGF-β: transforming/tumor growth factor β; TIMP: tissue inhibitor of MMPs; TNF-α: tumor necrosis factor-α; u-: urine level of; u-creat: urine level of creatinine; VEGF: vascular endothelial growth factor.
Phytoagents active in diabetic nephropathy classified according to their mechanism of action. The marker (H) was used to signal human studies.
| Aggressive factors | |
|---|---|
| Glucose metabolism | |
| Serum glucose level | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Insulin resistance |
|
|
| |
| Oxidative/nitrosative stress | |
| Oxidative stress | (-)-Epigallocatechin-3-gallate [ |
| Lipid peroxidation (LPO) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Nitrosative stress | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
|
| |
| Antioxidant protection | |
| Antioxidant capacity | Berberine [ |
| Catalase (CAT) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Free thiols | (+)-Catechin [ |
| Glutathione peroxidase (GPx) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Glutathione reductase (GRed) | Coccinia indica [ |
| Reduced glutathione (GSH) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Glutathione S-transferase (GST) |
|
| Superoxide dismutase (SOD) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
|
| |
| Advanced glycation end-products (AGEs) | |
| AGEs | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Receptor for AGEs (RAGE) | Berberine [ |
|
| |
| Autophagy | |
| AMPK | Astragaloside IV [ |
| AMPK/mTOR |
|
| AMPK/mTOR/ULK1 | Mangiferin [ |
| HO-1 | Celastrol [ |
| Hypoxic stress: SIRT-1, Foxo3/Bnip3/Hif1a | Resveratrol [ |
| MAPKs (p38/, JNK, ERK 1/2), NF- | Ferulic acid [ |
| miR-141-3p/PTEN/Akt/mTOR | Triptolide [ |
| miR-383-5p | Resveratrol [ |
| miRNA-18a-5p | Resveratrol [ |
| Oxidative stress (HO-1, p47phox) |
|
| PI3K/AKT | Curcumin [ |
| Pim1/p21/mTOR | Hispidulin [ |
| Promyelocytic leukemia zinc finger protein | Tangshen Formula [ |
| SIRT-1 |
|
| SIRT1/NF- | astragaloside IV [ |
|
| Tripterygium glycosides [ |
|
| |
| Pathways | |
| Akt | (-)-Epigallocatechin-3-gallate [ |
| Angiotensin II (AT2) | (-)-Epigallocatechin-3-gallate [ |
| Inducible nitric oxide synthase (iNOS) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Cyclooxygenase 2 (COX-2) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Endoplasmic reticulum stress (ER stress) |
|
| c-Jun NH2-terminal kinase (JNK) |
|
| Extracellular regulated protein kinases (ERK1/2) | (-)-Epigallocatechin-3-gallate [ |
| Glycogen synthase kinase 3 | Emodin [ |
| Nuclear factor | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome | Dihydroquercetin [ |
| Smad (TGF- | Berberine [ |
| Sterol regulatory element-binding protein (SREBP) |
|
| Transforming/tumor growth factor | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| p38-mitogen-activated protein kinase (p38MAPK) | (-)-Epigallocatechin-3-gallate [ |
| Phosphatidylinositol 3-kinase (PI3K) | (-)-Epigallocatechin-3-gallate [ |
| Proteinkinase C (PKC) | Berberine [ |
| JNK (JNK-NF- | Astragaloside IV [ |
| Insulin receptor (IR) and insulin receptor substrate (IRS) | Huangqi decoction [ |
| Glucose transporter 1 and 4 (GLUT1, GLUT4) | Huangqi decoction [ |
| G protein-coupled receptor kinase (GRK)2, GRK3, GRK6 | Berberine [ |
| PGE2/EP1/G | Berberine [ |
| cAMP response element-binding protein (CREB) | Emodin [ |
| Cyclic adenosine monophosphate (cAMP) | Berberine [ |
|
| |
| Mediators | |
| Matrix metalloproteinase (MMP) | |
| MMP-1 |
|
| MMP-9 and MMP-9/TIMP-1 ratio | Berberine [ |
| Tissue inhibitor of MMPs- (TIMP-) 2 and MMP-2/TIMP-2 ratio | Berberine [ |
|
| |
| Cytokines | |
| IL-1 (interleukin-1) |
|
| IL-1 receptor (IL-1R) |
|
| IL-10 | Crocin [ |
| IL-12 | Curcumin analogue (B06) [ |
| IL-2 |
|
| IL-6 |
|
| IL-8 | Crocin [ |
| Interferon- |
|
| Tumor necrosis factor- |
|
|
| |
| Chemokines | |
| Monocyte chemoattractant/chemotactic protein-1 (MCP-1) | berberine [ |
|
| |
| Adhesion molecules | |
| Intercellular adhesion molecule-1 (ICAM-1) | Breviscapine [ |
| Vascular cell adhesion molecule-1 (VCAM-1) | Berberine [ |
|
| |
| Growth factors | |
| Vascular endothelial growth factor (VEGF) | Myricetin [ |
| Connective tissue growth factor (CTGF) | Emodin [ |
|
| |
| Cellular infiltration | |
| Macrophage infiltration | Breviscapine [ |
| Macrophage migration |
|
| Myeloperoxidase (MPO) | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
|
| |
| Diabetic nephropathy (DN) | |
| Apoptosis | |
| Apoptosis | Astilbin [ |
| HIF-1 | Berberine [ |
| Bcl-2-associated X protein (BAX) | Astilbin [ |
| B-cell lymphoma 2 protein (Bcl-2) | Astilbin [ |
| Bcl-2-associated death promoter (Bad) |
|
| Caspase-9 | Berberine [ |
| Caspase-12 | Astragaloside IV [ |
| Caspase-3 | Astilbin [ |
| Caspase-1 | Dihydroquercetin [ |
| Poly (ADP-ribose) polymerase (PARP) |
|
| Survivin (antiapoptotic marker) | Secoisolariciresinol diglucoside [ |
| C/EBP homologous protein (CHOP) | Astragaloside IV [ |
|
| |
| Glomerulosclerosis (GS), fibrosis, extracellular matrix (ECM) expansion | |
| Collagen 1 | Berberine [ |
| Collagen 3 | Tangshen Formula [ |
| Collagen 4 |
|
| Fibronectin | (-)-Epicatechin 3-O-gallate and (-)-epigallocatechin 3-O-gallate [ |
| Laminin |
|
|
| |
| Endothelial dysfunction | |
| Endothelial dysfunction |
|
| Endothelin-1 | (+)-Catechin [ |
| Homocysteine |
|
|
| |
| Podocytes, foot processes, slit diaphragms | |
| Podocyte apoptosis | Silybin [ |
| Podocyte foot processes effacement | Curcumin [ |
| Podocytes CD2-associated protein (markers of slit diaphragms reduced by HG) | Crocin [ |
| Podocyte slit diaphragm proteins (nephrin, podocin, and synaptopodin) | Puerarin [ |
| Podocin | Crocin [ |
| Nephrin | Crocin [ |
| Synaptopodin | Curcumin [ |
| Desmin | Curcumin [ |
|
| |
| Epithelial-mesenchymal transdifferentiation (EMT) | |
| Caveolin-1, | Curcumin [ |
| Integrin-linked kinase | Rhein [ |
| Vimentin | Curcumin [ |
|
| |
| Protectors | |
| Akt | Astilbin [ |
| Nuclear factor erythroid-derived 2 (Nrf2) |
|
| NAD(P)H:Quinone oxidoreductase 1 (NOX1) | Moringa isothiocyanate [ |
| Glutamate cysteine ligase catalytic subunit (GCLC) | Moringa isothiocyanate [ |
| 5′ adenosine monophosphate-activated protein kinase (AMPK) | Cocoa enriched with polyphenols [ |
| Sirtuin 1 (SIRT1) | Puerarin [ |
| Peroxisome proliferator-activated receptor- |
|
| Peroxisome proliferator-activated receptor- |
|
| E prostanoid receptor 4/protein G | Berberine [ |
Figure 2Graphical abstract: phytoagents active in diabetic nephropathy grouped according to their mechanism of action. Phytoagents: Abel.m: Abelmoschus manihot; All.s: Allium sativum; Anog.a: Anogeissus acuminata; Art.c: Artemisia campestris; astil: astilbin; astrag: astragaloside IV; Bac.m: Bacopa monnieri; berb: berberine; brev: breviscapine; cat: (+)-catechin; Chlor.p: Chlorella pyrenoidosa; Clad.g: Cladophora glomerata; Cocc.i: Coccinia indica; cocoa+p: cocoa enriched with polyphenols; Cor.t: Coreopsis tinctoria; Cord.m: Cordyceps militaris; Corn.o: Cornus officinalis; croc: crocin; curc: curcumin; curcB06: curcumin analogue B06; CW: coconut water; DH: Danhong; DHQ: dihydroquercetin; Diosc.b: Dioscorea bulbifera; diosg: diosgenin; d-pin: d-pinitol; ECG: (-)-epicatechin 3-O-gallate (Camellia sinensis); EGCG: (-)-epigallocatechin 3-O-gallate; ellag: ellagic acid; emo: emodin; Flamm.v: Flammulina velutipes; Frag.a: Fragaria × ananassa; gins: ginseng; HD: Huangqi decoction; Hib.s: Hibiscus sabdariffa; Hydr.p: Hydrangea paniculata; Hyp.p: Hypericum perforatum; isorh: isorhamnetin; MoITC: moringa isothiocyanate; Mor.a: Morus alba; myric: myricetin; Paed.f: Paederia foetida; Paeo.e: Paeonia emodi; Paeo.l: Paeonia lactiflora; Paeo.s: Paeonia suffruticosa; PCA: purple corn anthocyanins; Phys.a: Physalis angulata; Pleur.e: Pleurotus eryngii; Prun.v: Prunella vulgaris; Psor.c: Psoralea corylifolia; puer: puerarin; Pun.g: Punica granatum; QDD: Qidan Dihuang decoction; querc: quercetin; Rhe.r: Rheum ribes; Sal.c: Salacia chinensis; SDG: secoisolariciresinol diglucoside; silyb: silybin; silym: silymarin; Spir.n: Spirogyra neglecta; SYFSF: Shen-Yan-Fang-Shuai Formula; TD: Tangke decoction.